Kambhampati S, et al. - Via conducting a retrospective case series of patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh class B (CPB) cirrhosis who were treated with nivolumab and were enrolled in the University of California at San Francisco Hepatobiliary Tissue Bank and Registry, researchers investigated the safety and efficacy of nivolumab in these patients. Among a total of 18 patients, 72% (13 of 18 patients) reported the previous treatement with sorafenib. A grade ≥3 adverse event (AE) was reported in the majority of patients (94%; 17 of 18 patients), with 28% of patients (5 of 18 patients) reporting treatment-related grade ≥3 AEs indicating high rates of AEs in patients with CPB HCC. The frequency of irAEs in this work was similar to that of patients with Child-Pugh class A HCC in the CheckMate 040 trial. Further, they noted prolonged tumor responses in a subset of patients.